reports
- Cosmin Filker
- Marcel Goldmann
Sygnis AG - Research Report (Anno) - 18.06.18
SYGNIS AG, headquartered in Heidelberg, is a life sciences company listed on the Prime Standard of the Deutsche Börse. The company focuses on the development and marketing of innovative molecular biology technologies in the NGS (next-generation sequencing) and the immuno-diagnostic sector. Its most important products currently on the market are TruePrimeTM (DNA amplification), SunScriptTM (transcribing RNA into DNA), RunBlue (DNA and protein separation and purification), Lightning Link (DNA and ...
- Cosmin Filker
- Marcel Goldmann
Sygnis AG - Researchstudie (Anno) - 18.06.18
Die SYGNIS AG ist spezialisiert auf die Entwicklung und Vermarktung von proprietären Technologien und bietet eine breite Palette verschiedener kommerzieller Produkte, die die wichtigsten Herausforderungen in der Molekularbiologie adressieren. Mit dem Erwerb der Expedeon Holdings, Ltd. Mit Sitz in Cambridge, Großbritannien, im Juli 2016 hat SYGNIS sein Produktportfolio um den Bereich Proteomik ergänzt. Durch diese bedeutende Erweiterung des Produktportfolios deckt SYGNIS nun den gesamten Arbeitsp...
- Cosmin Filker
Organic and Acquisitive Growth in Sales and Results; Critical Mass Rea...
SYGNIS AG, headquartered in Heidelberg, is a life sciences company listed on the Prime Standard of theDeutsche Börse. The company focuses on the development and marketing of innovative molecular biologytechnologies in the NGS (next-generation sequencing) sector. Its most important products currently on themarket are TruePrimeTM (DNA amplification), SunScriptTM (transcribing RNA into DNA), RunBlue (DNA andprotein separation and purification) and Lightning Link (DNA and protein labeling) which are...
- Cosmin Filker
„Organisches und anorganisches Umsatz- und Ergebniswachstum; Kritisc...
Die SYGNIS AG mit Sitz in Heidelberg ist ein im Prime Standard der Deutschen Börse gelistetes Life Science-Unternehmen. Das Unternehmen fokussiert sich auf die Entwicklung und Vermarktung von neuartigenmolekularbiologischen Technologien im Bereich des NGS (Next Generation Sequencing). Die wichtigstenderzeit in der Vermarktung befindlichen Produkte sind TruePrimeTM (DNA-Amplifikation), SunScriptTM (Übersetzung von RNA in DNA), RunBlue (DNA-Trennung und -Reinigung) und Lightning Link (DNA- und Pro...
- Cosmin Filker
Research Comment: Planned takeover of another profitable company - Inn...
Die SYGNIS AG mit Sitz in Heidelberg und Madrid ist ein im Prime Standard der Deutschen Börse gelistetes Life Science-Unternehmen. Das Unternehmen fokussiert sich auf die Entwicklung und Vermarktung von neuartigen molekularbiologischen Technologien im Bereich des NGS (Next Generation Sequencing). Die wichtigsten derzeit in der Vermarktung befindlichen Produkte sind TruePrimeTM (DNA-Amplifikation) sowie SunScriptTM (Übersetzung von RNA in DNA), welche sowohl im Rahmen einer Eigenvermarktung sow...
- Cosmin Filker
Research Comment: Ãœbernahme eines weiteren profitablen Unternehmens g...
Die SYGNIS AG mit Sitz in Heidelberg und Madrid ist ein im Prime Standard der Deutschen Börse gelistetes Life Science-Unternehmen. Das Unternehmen fokussiert sich auf die Entwicklung und Vermarktung von neuartigen molekularbiologischen Technologien im Bereich des NGS (Next Generation Sequencing). Die wichtigsten derzeit in der Vermarktung befindlichen Produkte sind TruePrimeTM (DNA-Amplifikation) sowie SunScriptTM (Übersetzung von RNA in DNA), welche sowohl im Rahmen einer Eigenvermarktung sow...
- Cosmin Filker
Research Report Update - Q3 Report
​SYGNIS AG is a life sciences company listed in the Prime Standard of the German Stock Exchange (Deutsche Börse). The company focuses on the development and marketing of innovative molecular biology technologies in the NGS (next-generation sequencing) sector. Its most important products currently on the market are TruePrimeTM (DNA amplification) and SunScriptTM (translating RNA into DNA), which are sold both through their own marketing and through non-exclusive sales partnerships. Other produ...
- Cosmin Filker
Researchstudie Update - Q3 Zahlen
​Die SYGNIS AG mit Sitz in Heidelberg und Madrid ist ein im Prime Standard der Deutschen Börse gelistetes Life Science-Unternehmen. Das Unternehmen fokussiert sich auf die Entwicklung und Vermarktung von neuartigen molekularbiologischen Technologien im Bereich des NGS (Next Generation Sequencing). Die wichtigsten derzeit in der Vermarktung befindlichen Produkte sind TruePrimeTM (DNA-Amplifikation) sowie SunScriptTM (Übersetzung von RNA in DNA), welche sowohl im Rahmen einer Eigenvermarktung ...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Update: Electrifying sales potential
Sygnis intends to acquire a private UK proteomics company, Expedeon, funded by issuing up to 20.5m shares. Sygnis produces innovative molecular biology kits, while Expedeon makes well designed but standard consumable products for protein analysis. Expedeon has a UK- and US-focused, 13-person sales and marketing team and a five-year sales CAGR of about 20%. The deal will complete in mid-year and integration and training will take some months. Sygnis expects to see sales synergies from 2017 and mi...
Update: Rights issue to fund market development
Sygnis sells its own-brand TruePrime and SunScript kits through its website and an international distributor network. A rights issue for €6.7m plus a €0.6m debt conversion was announced on 17 November. This will allow Sygnis to develop its brand, extend its product range of kits and enter the crucial US market. Kits may also be sold as OEM products for next-generation sequencing. A kit for cell-free DNA “liquid biopsy†analysis, a high growth area, is planned for 2016. Cash at 30 Septemb...
QuickView: Truly sunny sequencing technologies
Sygnis uses its own website and an international distributor network to sell its own-brand TruePrime kits for gene analysis. A new enzyme, SunScript, has been added to the range. A new product for research in cancer diagnosis and monitoring could be added in 2016. These kits offer increased reliability and efficiency over older products, due to the novel engineered enzymes designed and produced by Sygnis. Cash at 30 June was €1.3m. H115 had revenues of €196k; H1 cash outflow was €2.4m.
Update: Adding to the brand
Sygnis sells its own-brand TruePrime kits through its website and an international distributor network. A new enzyme, SunScript, has been added to the range. Kits may also be sold as OEM products with next-generation sequencing systems. A new kit for research in cancer diagnosis and monitoring could be added in 2016. Cash at 31 March was €2.5m. Q115 had revenues of €76k; total cash outflow was €1.29m.
Update: True value through TruePrime
Sygnis uses its leading molecular biology expertise to target the growing genomic amplification market worth about $100m. It has developed a new major enzyme, TthPrimPol, which directly “primes†DNA for amplification. This allows Sygnis to sell its own-brand TruePrime kits direct to scientists from Q115. Kits might also be sold as OEM products alongside next-generation sequencing systems. Cash at 30 September was €0.36m. A €5m funding has been announced at €2/share to fund the TruePrim...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.